Bioventus (BVS) director logs open-market sale of 12,000 shares

Rhea-AI Filing Summary

Bioventus Inc. director Michelle McMurry-Heath reported an open-market sale of 12,000 shares of Class A common stock. The shares were sold at a weighted average price of $8.7866, in multiple trades between $8.73 and $8.81. After the transaction, she directly holds 44,997 shares.

Insider Trade Summary

Net Seller: 12,000 shares ($105,439)

Net Sell 1 txn

Insider McMurry-Heath Michelle

Role Director

Sold 12,000 shs ($105K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	12,000	$8.7866	$105K

Holdings After Transaction: Class A Common Stock — 44,997 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McMurry-Heath Michelle

(Last) (First) (Middle)

4721 EMPEROR BOULEVARD, SUITE 100

(Street)

DURHAM NC 27703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bioventus Inc. [ BVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	03/11/2026		S		12,000	D	$8.7866(1)	44,997	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.73 to $8.81, inclusive. Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Remarks:

	/s/ Anthony D'Adamio, Attorney-in-Fact	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Bioventus (BVS) disclose in this Form 4?

Bioventus disclosed that director Michelle McMurry-Heath sold 12,000 shares of Class A common stock. The transaction was an open-market sale, reported as a single Form 4 entry, reflecting a routine insider share disposition rather than any derivative exercise or grant activity.

At what price did the Bioventus (BVS) director sell her shares?

The director sold 12,000 Bioventus shares at a weighted average price of $8.7866. According to the footnote, the sales occurred in multiple trades, with individual transaction prices ranging from $8.73 to $8.81 per share during the reported trading session.

How many Bioventus (BVS) shares does the director hold after this sale?

Following the reported sale, director Michelle McMurry-Heath directly holds 44,997 shares of Bioventus Class A common stock. This figure represents her remaining direct equity position as reported in the Form 4 and provides context for the scale of the 12,000-share disposition.

Was the Bioventus (BVS) insider transaction an open-market sale or another type?

The transaction was an open-market sale of common stock, coded “S” on the Form 4. It is described as a sale in the open market or a private transaction, without any associated option exercise, tax withholding, gift, or derivative conversion activity in this filing.

Does the Bioventus (BVS) Form 4 mention a trading plan for this sale?

The Form 4 footnote explains the weighted average sale price and price range but does not reference a Rule 10b5-1 trading plan. It only notes that detailed trade-by-trade pricing information is available upon request from the issuer, security holders, or regulatory staff.